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 Sources of GTIs in API production:
1. Introduction
Székely G. et al., Chem. Rev., 2015, 115, 8182-8229.
(Madeleine Price Ball’s Figure, GNU Free Documentation License)
 GTIs:
 Broad range of chemical families (structural
alerts)
 Electrophilic species
 React with DNA; can lead to strand breaks 
 Associated carcinogenic risk
Targeted nucleophilic sites of the DNA bases.  
1. Introduction
Székely G. et al., Sep. Purif. Technol., 2012, 86, 190-198.
EMEA Guidelines on the “Limits on Genotoxic Impurities”, EMEA/CHMP/QWP/251344/2006, 2006.
FDA Guidance for Industry Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches; U.S. Department of Health and Human
Services, 2008.
 Removal of GTIs from APIs is of major importance:
 Strict regulations (FDA, EMEA) defined a Threshold of Toxicological Concern (TTC) :
TTC = 1.5 µg/day
 TTC corresponds to the probability of one patient in 1,000,000 to manifest the risk of having
cancer.
 Below the TTC there is no appreciable risk to human health.
 GTI limits in APIs are calculated by dividing the TTC value by the maximum daily dose (g/day).
1. Introduction





 Several purification stages





 To achieve GTI content in the API
at low levels is in many cases
extremely difficult .
 Production of APIs with low GTI
contents is a major concern for
API-manufacturing companies.
2. Main Goal
To design new adsorbers as GTI scavengers.
Advanced purification technique - organic solvent co mpatible 
platforms. 
























Sellergren B. et al., WO2012172075 A1, 2012.
Székely G. et al., Sep.Purif. Technol., 2012, 86, 190-198.
Kupai et al., ACS Appl. Mater. Interfaces, 2015, 7, 9516-9525.
3.1. MIP: Concept
- Drug delivery systems
- Sensors
- Solid phase extraction
- Chromatography
Molecularly Imprinted Polymer (MIP)
 polymerization in the presence of a template molecule
 after polymerization, the template is removed and a cavity remains
 the polymer binds specifically target analytes, providing an accurate mechanism of recognition
3.1. MIP: Model compounds
API: Mometasone furoate





API: glucocorticoid steroid used 
topically to reduce inflammation of 
the skin or in the airways:
• treatment of inflammatory skin 
disorders (such as eczema and 
psoriasis)
• allergic rhinitis (such as hay 
fever)
• asthma for patients unresponsive 
to less potent corticosteroids
Heggie W. et al., US 6177560, 2001.
Székely G. et al., Green Chem., 2013, 15, 210-225.
3.1. MIP: Synthesis
 DMAP (GTI) genotoxicity:
 two stuctural alerting groups: aromatic and alkyl amine
 aromatic amine in vivo decomposition leads to 
electrophilic reactive species:
- attack nucleophilic centre(s) of DNA 
- associated carcinogenic risk
Snodin et al., Org. Process Res. Dev., 2010, 14, 960-976.















T MAA EGDMA Method
MIP1 0.1 0.4 1 1
MIP2 0.1 0.4 2 1
MIP3 0.4 0.4 4 1
MIP4 0.4 0.4 4 2
 Porogen: DCM
 T: template
 MAA: functional monomer
 EGDMA: cross-linker
 Method 1: 16h at 40 ºC + 4 h at 65ºC



















t = 24 h rpm = 60
T = RT V = 1 mL
Solvent: DCM Detection: HPLC
40ºC / 65ºC
65ºC
3.1. MIP: Adsorber Selection




























MIP2 207 0,024 5.6
NIP2 242 0,025 7.3




















Esteves T. et al., Sep. Purif. Technol., 2016, 163, 206-214.
 Kinetic experiments: maximum 93% of GTI




































Esteves T. et al., Sep. Purif. Technol., 2016, 163, 206-214.
 Multifactorial design:
x1 – DMAP concentration in ppm
x2 – MIP2 in mg
x3 – Solution volume in mL
 Univariable design:
Bind. – binding percentage (DMAP removal from solution)
 A two level face-centered design was performed in order to optimize the 3 factors.
Factor Low level (-1) Central point (0) High level (+1)
x1 (ppm) 7 100 600
x2 (mg) 37.5 75 100
x3 (mL) 1.5 3 5
3.1. MIP: Experimental Design - GTI Binding
Esteves T. et al., Sep. Purif. Technol., 2016, 163, 206-214.
SS DF MS F-value p-value
DMAP 33.61 1 33.61 442.00 0.0302
DMAP2 3021.29 1 3021.29 39727.66 0.0032
MIP 830.71 1 830.71 10923.27 0.0061
Volume 842.11 1 842.11 11073.16 0.0060
DMAP x MIP 485.43 1 485.43 6383.02 0.0080
DMAP x Volume 909.69 1 909.69 11961.80 0.0058
Lack of fit 96.70 8 12.09 158.95 0.0613
Pure Error 0.076 1 0.076
Total SS 6169.77 15
 ANOVA performed to the model with
only statistically significant terms
considered (p < 0.05).
 Response surface plots. Effect of:
A) DMAP concentration and MIP quantity;
B) DMAP concentration and solution volume 
on the binding.
The model is 
statistically significant 
(p > 0.05)
3.1. MIP: Experimental Design - GTI Binding
Model predictions:
250 < DMAP (ppm) < 350
75 < MIP (mg) < 100
Volume = 1.5 mL




DMAP binding 93% 88%
Meta binding 12% 4%
mg DMAP / g Meta 0.79 1.25
T = RT
MIP2 = 50 mg
Detection: RP-HPLC
Solvent: DCM
flow: 0.15 – 0.42 mL/min
DMAP: 100 ppm
Meta: 10,000 ppm
3.1. MIP: Scale -up (SPE)
Esteves T. et al., Sep. Purif. Technol., 2016, 163, 206-214.
3.1. MIP: Process Design
100 mgDMAP/gMeta
81.25 mgDMAP/gMeta 45,14 mgDMAP/gMeta 18.08 mgDMAP/gMeta
Application Nasal Spray Cream
Maximum daily dose 200 µg 2 mg
Nº Steps 4 5
API loss 16% 20%
GTI removal 98% > 99%
Target (mg DMAP / g Meta) 7.50 0.75
Obtained (mg DMAP / g Meta) 1.65 < 0.37






Esteves T. et al., Sep. Purif. Technol., 2016, 163, 206-214.
3.1. MIP: Process Design
100 mgDMAP/gMeta
3.12 mgDMAP/gMeta
Székely G. et al., Green Chem., 2013, 15, 210-225.
Esteves T. et al., Sep. Purif. Technol., 2016, 163, 206-214.
Rejection (%) at 10 bar
Meta (API) 99.0 ± 0.1
DMAP (GTI) 15.1 ± 0.3
Hybrid process:
0.38 mgDMAP/gMeta
Application Nasal Spray Cream
Nº Steps 1 2
API loss 4% 8%
Target (mg DMAP / g Meta) 7.50 0.75























Application Nasal Spray Cream
Maximum daily dose 200 µg 2 mg
Method SPE OSN SPE OSN + SPE
Nº Steps 4 1 5 2
API loss 16% 4% 20% 8%
GTI removal (%) 98% 97% > 99% > 99%
Target (mg DMAP / g Meta) 7.50 0.75
Obtained (mg DMAP / g Meta) 1.65 3.12 < 0.37 0.38
3.1. MIP: Process Design
Esteves T. et al., Sep. Purif. Technol., 2016, 163, 206-214.
3.2. PBI-adenine : Concept
Vicente A. I. et al., Sep. Purif. Technol., 2017, 179, 438-448.
 Polymer: PBI
 DNA base: adenine
(polybenzimidazole)
3.2. PBI-adenine : Model Compounds
 GTIs: DNA alkylating agents  APIs
• Alkyl tosylate • Alkyl mesylate • Dihaloalkane
• Epoxide • Dimethyl sulfate
Vicente A. I. et al., Sep. Purif. Technol., 2017, 179, 438-448.
Esteves T. et al., 2017, manuscript under preparation.
• Meta • Beta
3.2. PBI-adenine : Synthesis
Synthetic strategy for alkylation of adenine and the PBI-A x% polymer:
Vicente A. I. et al., Sep. Purif. Technol., 2017, 179, 438-448.








































t = 24 h rpm = 200
T = RT V = 1 mL










































) BET Surface areaAdenine incorporation
MPTS
Vicente A. I. et al., Sep. Purif. Technol., 2017, 179, 438-448.
3.2. PBI-adenine : Characterization
 1H NMR studies: DMSO-d6
PBI
Vicente A. I. et al., Sep. Purif. Technol., 2017, 179, 438-448.
4. Concluding Remarks : MIP 
 A MIP designed to target DMAP GTI was sucessfully synthesized.
 Efective removal of 93% of DMAP (2 mg DMAP / g MIP) with a loss of 12% of Meta
(API) due to non-specific binding in batch experiments.
 Two step hybrid process design:
 OSN + SPE (MIP)
 92% API recovery
 > 99% GTI removal
4. Concluding Remarks : PBI-adenine
 An adsorber was successfully designed to target DNA alkylating agents .
 Process design:
 Efective removal of 96% of MPTS (2 mg MPTS / g PBI-A12%)
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